Milan, Italy

Giuseppe Marazzi

USPTO Granted Patents = 4 


 

Average Co-Inventor Count = 5.8

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2012-2024

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: **Giuseppe Marazzi: Innovator in Pharmaceutical Chemistry**

Introduction

Giuseppe Marazzi, an accomplished inventor based in Milan, Italy, has significantly contributed to the field of pharmaceutical chemistry. With a total of four patents, he is known for his innovative work on contrast agents that enhance medical imaging techniques.

Latest Patents

Among his most recent inventions is the patent concerning Gadolinium-bearing PCTA-based contrast agents. This invention focuses on the RRR/SSS pair of enantiomers of Gd(PCTA-tris-glutaric acid). It covers not only the single enantiomers of the pair but also pharmaceutically acceptable salts and their amide derivatives. The compositions that comprise at least 50% of these compounds have promising implications for enhancing imaging procedures.

Career Highlights

Giuseppe Marazzi has made impactful strides in his career by working with notable companies in the pharmaceutical industry, including Bracco Imaging S.p.a. and Sigma-Tau Industrie Farmaceutiche Riunite S.p.a. His experience in these organizations has bolstered his ability to innovate and develop new chemical agents.

Collaborations

Throughout his career, Marazzi has collaborated with talented professionals, including Roberta Napolitano and Luciano Lattuada. Together, they have contributed to advancing research and development in the pharmaceutical sector.

Conclusion

In conclusion, Giuseppe Marazzi stands out as a prominent inventor in the realm of pharmaceutical chemistry. His patents, particularly in Gadolinium-bearing PCTA-based contrast agents, showcase his commitment to innovation and improvement in medical imaging technologies. His collaborations and career milestones further underline the significant impact he has made on the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…